The mitochondrial enzyme manganese superoxide dismutase (MnSOD) has been shown to have two faces with regard to its role in tumor development. On the one side, it is well documented that overexpression of MnSOD slows down cancer cell growth, whereas on the other side MnSOD also has a metastasis-promoting activity. We set out to examine the role of MnSOD in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, thought to be a first-line tumor surveillance mechanism and failure to undergo apoptosis might contribute to metastasis formation. We show that overexpression of MnSOD at moderate levels is able to protect cells from TRAIL-induced apoptosis. While caspase-8 activation and Bid cleavage were not affected by MnSOD, we detected a marked decrease in caspase-3 activation pointing to a mitochondrial resistance mechanism. Indeed, we found that MnSOD-overexpressing cells showed reduced cytochrome c and no Smac/DIABLO release into the cytosol. The resulting lack of X-linked inhibitor of apoptosis (XIAP) inhibition by cytosolic Smac/DIABLO most likely caused the TRAIL resistance as RNAi against XIAP-rescued caspase-3 activity and TRAIL sensitivity. Our results show that reactive oxygen species are involved in TRAIL-induced Smac/DIABLO release and in TRAIL-triggered apoptosis. Hence, high levels of MnSOD, which decompose and neutralize these reactive oxygen species, might contribute to metastasis formation by allowing disseminated tumor cells to escape from TRAIL-mediated tumor surveillance. As part of TRAIL regimens, adjuvant treatment with XIAP inhibitors in the form of Smac/DIABLO mimetics or MnSOD inhibitors might be able to break TRAIL resistance of malignant tumor cells.
Introduction
The tumor-specific apoptosis-inducing activity of the tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) suggests it is a promising tumoricidal agent (Ashkenazi et al., 1999; Duiker et al., 2006) . However, only about 50% of all cancer cells tested so far respond to TRAIL, leaving the other half, including some malignant tumors with high metastasizing potential, resistant to the apoptosis-inducing effects of TRAIL (Vigneswaran et al., 2005; Zhang and Fang, 2005) . Moreover, endogenously produced TRAIL has been described as a tumour-surveillance mechanism Takeda et al., 2002; Wajant, 2006) and factors that impair this function by blocking apoptosis in malignant cells can contribute to the escape of metastasizing tumor cells from this TRAIL-mediated control. Hence, a molecular understanding of the resistance mechanisms in tumors is the first step in the identification of strategies that can circumvent these hurdles for TRAIL cancer therapy and possibly more importantly may aid in the development of approaches that promote the inherent antimetastasizing potential of endogenously produced TRAIL.
Various TRAIL-resistance mechanisms have been identified stretching from low TRAIL-receptor (TRAIL-R1 and TRAIL-R2), increased levels of the Fas-associated death domain (FADD)-like interleukin1b-converting enzyme-inhibitory protein (Thome et al., 1997) or the antiapoptotic caspase-8L splice variant to loss of the proapoptotic Bcl-2 members such as Bax as well as overexpression of the antiapoptotic members Bcl-2 and/or Bcl-x L . In addition, nuclear factor-k B (NF-kB), mitogen-activated protein kinases and decreased Smac/DIABLO release from mitochondria have been implicated in TRAIL resistance in certain types of cancer cells (Zhang and Fang, 2005) .
We were particularly interested in putative resistance mechanisms that are prominently present in metastasizing tumors and that could explain the marked TRAILresistance in malignant tumor cells as compared to cells from early-stage disease. A gene product that has been reported to be particularly highly expressed in metastases as compared to early-stage growth, where it is frequently found at low levels, is manganese superoxide dismutase (MnSOD) (Oberley, 2005) . MnSOD is a mitochondrial matrix protein that catalyses the dismutation of superoxide radicals (O 2 À ) to hydrogen peroxide (H 2 O 2 ) (Kahl et al., 2004; Culotta et al., 2006) . Quantitative analyses revealed that colorectal carcinomas and liver metastases expressed up to four times more MnSOD than normal mucosa and that adenomas expressed intermediate MnSOD levels that increased significantly with the grade of dysplasia (Janssen et al., 1999; Toh et al., 2000) . Moreover, it has been shown that a high MnSOD content of colorectal carcinomas was associated with poor 5-year overall survival of the patients with colorectal cancer (Janssen et al., 1999; Nozoe et al., 2003) . Similar findings were obtained with other types of cancer (Izutani et al., 1998; Malafa et al., 2000; Lewis et al., 2005) .
MnSOD is positively regulated by NF-kB and the connection between NF-kB and tumor progression and metastatic growth has been well documented (Greten et al., 2004; Karin and Greten, 2005; Papa et al., 2006) . Thus, elevated NF-kB activity levels as triggered by the proinflammatory milieu of a growing tumor might eventually lead to increased MnSOD expression. This, in return, has been linked to increased activity levels of matrix metalloproteinases, which are required by tumor cells to break away from the primary tumor and to invade other tissues (Wenk et al., 1999; Zhang et al., 2002) . Therefore, high MnSOD levels might be important to facilitate the metastatic process. Such elevated MnSOD activities can also protect cells from various intra-and extracellular stimuli and stresses (Mantymaa et al., 2000; Kahl et al., 2004) , also including ischemia/reperfusion (Zwacka et al., 1998b) and TNF-a (Wong et al., 1989; Li and Oberley, 1997) . This antiapoptotic function might be essential for the survival of disseminating tumor cells in the lymphatic and vascular system as well as in distal organs. Hence, elevated MnSOD levels might contribute to metastasis formation through more than one molecular mechanism.
As TRAIL appears to be a particularly important tumor surveillance factor, we wondered whether elevated levels of MnSOD could render colorectal cancer cells resistant to TRAIL-induced apoptosis. Furthermore, we also wanted to test potential therapeutic strategies to overcome such resistance. We found that MnSOD can protect human colorectal cancer cells from TRAIL-induced apoptosis and that targeting the Xlinked inhibitor of apoptosis (XIAP) by RNAi (Braeuer et al., 2006) could recover the TRAIL sensitivity in such cells. This strategy might offer a way to increase the TRAIL sensitivity and the potency of the TRAILmediated natural tumor surveillance in malignant and invasive colorectal tumors as well as other types of cancer.
Results

Overexpression of MnSOD in human colorectal cancer cells HCT116
We established HCT116 clones that show moderate, stable overexpression of human MnSOD. The transgenic MnSOD protein levels of two MnSOD clones, HCTMnS9 and HCTMnS14 (MnS9 and MnS14) in comparison to a control clone (HCTCon or con) are shown in a western blot in Figure 1a . As we had established early on that HCT116 cells and HCTCon have similar MnSOD levels and do not differ in their TRAIL responses (data not shown), we only show the results for HCTCon. HCTCon cells were derived by transfection of the plasmid, carrying only the antibiotic resistance gene. Next, we tested whether the overexpression resulted in increased MnSOD activity. Figure 1b shows the results of this nitroblue tetrazolium (NBT)-based activity test. The clones 9 and 14 possess four-to fivefold elevated levels of MnSOD activity. To ascertain that overexpression of MnSOD did not change the normal mitochondrial localization, we analysed our clones by laser imaging fluorescence microscopy ( Figure 1c ). For this purpose, cells were loaded with MitoTrackerGreen FM and costained with antiMnSOD antibody followed by a secondary antibody conjugated to Carbocyanin 3 (Cy3). Comparison of HCTCon cells on the one side and HCTMnS9 and HCTMnS14 on the other showed that in the two overexpressing clones, the transgenic MnSOD localizes to mitochondria.
After having established functional transgenic MnSOD expression, we measured TRAIL-induced apoptosis in HCTMnS9 and HCTMnS14 and compared it to HCTCon cells.
MnSOD protects colon cancer cells from TRAIL-induced apoptosis
We treated HCTCon, HCTMnS9 and HCTMnS14 with 5 ng/ml TRAIL for 24 h. Apoptosis was then measured by a DNA-hypodiploidity assay as described by Nicoletti et al. (1991) . MnSOD-overexpressing cells were almost completely protected from the cell-killing effects of TRAIL, whereas HCTCon cells showed cell death rates of 45% and above (Figure 2a) . In addition, we tested apoptosis over a longer period of time (0-72 h), but still could not find onset of significant levels of apoptosis in the two MnSOD clones (data not shown). To verify our results with a second, independent method, we stained our cells after TRAIL treatment with Annexin V and propidium iodide (PI). The representative results depicted in Figure 2b are in line with the Nicoletti-assay data and demonstrate that MnSOD-overexpressing HCT116 cells are resistant to TRAIL. While HCTCon cells show 58% Annexin V positivity, the two clones are almost completely resistant to TRAIL with Annexin V-positive rates of 1.4% as shown in the summary diagram of the Annexin V/PI results of HCTCon and HCTMnS14 cells (Figure 2c ). HCTMnS9 showed the same results (data not shown). Furthermore, we tested additional MnSOD-overexpressing clones generated by selection with a different antibiotic (G418). They showed the same TRAIL resistance phenotype as HCTMnS9 and HCTMnS14 (data not shown). Furthermore, we generated an adenoviral vector (Ad.shRNAMnSOD) that produces a small RNAi hairpin motif capable of silencing endogenous (in HCTCon) and transgenic (in HCTMnS14) MnSOD expression (Figure 2d ). Knocking down endogenous MnSOD in HCTCon cells led to a small increase in TRAIL sensitivity (Figure 2e ). RNAi of MnSOD in HCTMnS14 cells restored their TRAILresponsiveness almost to the levels seen in the HCTCon cells (Figure 2e ). These results clearly indicate that the observed effect is directly caused by forced expression of MnSOD. However, we wanted to test the protective function of MnSOD with an alternative expression system. Therefore, we used an adenoviral vector that expresses MnSOD.
Adenovirally encoded MnSOD also protects from TRAIL-induced apoptosis Adenoviral vectors provide a tool to achieve transient expression of transgenes. We used a recombinant (Zwacka et al., 1998a) . Western blot (Figure 3a ) and immunofluorescence analyses (Figure 3b) show that the adenovirally encoded MnSOD is overexpressed compared to parental cells and localizes to mitochondria. After 24 and 48 h when MnSOD transgene expression was well established, cells were treated with 5 ng/ml of TRAIL, before apoptosis was measured another 24 h later. The apoptosis results show that Ad.MnSOD-transduced HCT116 cells were protected from the effects of TRAIL when compared to cells transduced with the control vector Ad.GFP (Figure 3c ). This demonstrates that transient as well as stable expression of MnSOD is able to block TRAILinduced tumor cell death in HCT116 cells. To test the protective effect of MnSOD in another cell line, we transduced HT-29 human colorectal cancer cells with Ad.MnSOD ( Figure 3d ). Treatment with TRAIL of such MnSOD-overexpressing HT-29 cells also showed apoptosis inhibition ( Figure 3e ). Next, we tested whether this protective effect of MnSOD is also long lasting and does not simply delay cell death. To this end, we analysed our cells by colony-forming assays (CFA). Figure 4a depicts representative plates of TRAILtreated HCTCon and HCTMnS14 cells after 12 days of culturing. Initially, cells were treated for 1 h with TRAIL, that is before visible onset of apoptosis, and 
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A Mohr et al then seeded at different concentrations into tissue culture plates. The quantified results revealed a 99.5% reduction in colony-forming units in TRAIL-treated HCTCon cells over untreated cells, whereas HCTMnS14 only showed a 45% reduction, once more demonstrating the protective effect of MnSOD ( Figure 4b ). Next, we wanted to understand the molecular mechanism of this MnSOD effect.
HCT116 cells overexpressing MnSOD have decreased TRAIL-induced caspase-3 activation
First, we analysed whether TRAIL-receptor expression was influenced by MnSOD overexpression. Figure 5a shows a representative fluorescence-activated cell sorting (FACS) analysis of the four TRAIL receptors (TRAIL-R1, TRAIL-R2, TRAIL-R3, TRAIL-R4) on HCTCon cells and the HCTMnS14 clone. No significant changes in TRAIL-receptor expression could be detected, ruling out downregulation of TRAIL-R1 and TRAIL-R2 or upregulation of the so-called decoy receptors TRAIL-R3 and TRAIL-R4 as a potential explanation for the TRAIL resistance of HCTMnS cells. Subsequently, we looked at basal levels and activation kinetics of caspase-8, Bid, caspase-3 and caspase-2 ( Figure 5b ) and found that caspase-8 and Bid levels as well as their activation was not altered in the MnSODexpressing clones as compared to HCTCon cells. Caspase-2 was not processed in either of the two cell types and basal levels did not vary, too. However, while pro-caspase-3 levels in untreated cells were not different, the activation of caspase-3 was greatly diminished in the HCTMnS clones. The cleavage pattern of caspase-3 in MnSOD-overexpressing cells was typical of a block in caspase processing exerted by XIAP, that is processing to the intermediate fragments was still intact, but the final cleavage to the active fragment (p17) was inhibited ( Figure 5b ). Therefore, we analysed caspase-3 activity following TRAIL treatment in HCTCon and HCTMnS clones and found that caspase-3 activity was indeed markedly reduced in MnSOD-overexpressing cells ( Figure 5c ). We, therefore, hypothesized that MnSOD prevents activation of the mitochondrial apoptosis pathway and consequently blocks essential, downstream molecular events such as the release of cytochrome c and Smac/DIABLO into the cytosol. To confirm the connection between caspase-8 activation and mitochondria, we designed and used an RNAi motif against Bid expressed as a small hairpin from an adenoviral vector. Bid is cleaved by caspase-8 and acts as tBid in concert with other Bcl-2 family members to engage mitochondria. The western blot in Figure 5d shows the functional silencing of Bid in HCT116 cells. The knock down of Bid results in a marked reduction of TRAIL-induced apoptosis, demonstrating the importance of the caspase-8 to Bid to mitochondria signalling pathway (Figure 5e ). Hence, we investigated the role of mitochondrial apoptosis factors in TRAIL-induced apoptosis in HCTCon and HCTMnS cells in more detail.
MnSOD overexpression leads to decreased cytochrome c and Smac/DIABLO release A measure for the involvement of mitochondria in apoptotic signalling is a decrease in the mitochondrial membrane potential (MMP). 3,3 0 dihexyloxacarbo cyanine (DIOC(6)3) is a fluorescent dye that emits a green fluorescent signal when it encounters normal mitochondria. The signal depends on the MMP and drops when the MMP is reduced or lost. HCTCon cells show a marked decrease in DIOC(6)3 signal following TRAIL stimulation, whereas the MnSOD-overexpressing cells maintained an almost normal MMP (Figures  6a and b) . Next, we wanted to know whether protection from MMP loss would also lead to a lack of release of important pro-apoptotic factors from mitochondria into the cytosol. Failure to release Smac/DIABLO upon TRAIL treatment in the MnS clones could mean that activity of XIAP is not neutralized leading to inhibition of caspase-3 and apoptosis. Therefore, we analysed cytochrome c and Smac/DIABLO release into the cytosol. We purified mitochondrial and cytosolic fractions following TRAIL treatment for 6-12 h and subjected the resulting protein lysates to western blot analysis. The results of this analysis are shown in Figure 6c . They demonstrate that in cells overexpressing MnSOD, cytochrome c release was substantially reduced whereas Smac/DIABLO release was completely blocked. These results point to inhibition of cytochrome c and/or lack of Smac/DIABLO release as molecular causes for MnSOD-mediated resistance to TRAIL. In order to identify the molecular factors that determine TRAIL-induced apoptosis levels downstream of mitochondria, we applied RNAi tools to knock down caspase-9 and XIAP.
RNAi against XIAP rescues the TRAIL resistance phenotype First, we analysed the activation of caspase-9 following TRAIL treatment in HCTCon cells compared to HCTMnS14. The western blot in Figure 6d shows that in HCTCon cells caspase-9 is activated after TRAIL stimulation, whereas this activation is substantially attenuated in HCTMnS14 cells. However, when we used RNAi to knock down caspase-9 in HCTCon cells (Figure 6e ), the TRAIL-induced levels of apoptosis did not decrease (Figure 6f ), indicating that caspase-9 is not essential and that diminished cytochrome c release in HCTMnS cells cannot account for their TRAIL resistance phenotype. Therefore, we analysed the blocked release of Smac/DIABLO as a potential key factor in the MnSOD-mediated TRAIL unresponsiveness. First, we compared the XIAP levels in HCTCon and HCTMnS14 and found no difference between the two cell lines, ruling out that MnSOD overexpression might have led to increases in XIAP thereby blocking apoptosis (Figure 6g ). Subsequently, an adenoviral vector expressing a small hairpin directed against XIAP (Ad.shRNAXIAP) was used to knock down protein levels of XIAP as shown in the western blot in Figure 6h . HCTCon cells as well as the MnSOD-overexpressing clone were transduced with Ad.shRNAXIAP for 48 h before TRAIL (5 ng/ml) was added. Following TRAIL treatment for 24 h, the cells were harvested and subjected to apoptosis assays. The results demonstrate (Figure 6i ). Furthermore, we tested caspase-3 activity in HCTCon and HCTMnS14 cells that were transduced with Ad.shRNAXIAP and subsequently treated with TRAIL. The results show that caspase-3 activity is increased in TRAIL-treated MnSOD-overexpressing cells transduced with Ad.shRNAXIAP as compared to cells treated with the Ad.shRNAEGFP control vector (Figure 6j ). These results were confirmed by western blotting of cell lysates from these cells revealing release of the XIAP-block of caspase-3 activation in Ad.shRNAXIAP-transduced cells treated with TRAIL (Figure 6k) . Thus, targeting XIAP might be a way to overcome TRAIL resistance that is caused by elevated MnSOD levels.
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Discussion
MnSOD is a protein with two faces. On the one side it has been termed a tumor suppressor, leading to growth arrest and senescence (Lam et al., 1997; Cullen et al., 2003; Behrend et al., 2005) , while on the other hand elevated MnSOD levels have been correlated to an invasive and metastatic phenotype (Malafa et al., 2000; Toh et al., 2000) . Metastasizing cells have to overcome a number of obstacles before they can successfully invade nearby tissues. These cells have to be able to break away from the primary tumor, invade the local host tissue, survive during the passage through the lymphatic or vascular system and finally proliferate at the metastatic site. One of the first steps in this complex process is that leaving cells degrade the basement membrane collagen of the extracellular matrix (ECM). The ECM separates the tumor from surrounding tissue and by degrading it, cancer cells are able to escape. A group of enzymes that has been shown to be involved in this process are matrix metalloproteases and their increased activity has been shown to correlate with the metastatic potential of a wide range of cancers (Liotta and Stetler-Stevenson, 1990; Egeblad and Werb, 2002; Deryugina and Quigley, 2006) . A possible mechanism by which MnSOD might contribute to the increased aggressiveness of tumors is the upregulation of these matrix-degrading metalloproteases (Wenk et al., 1999) . Hence, upregulation of MnSOD might be a mechanism by which tumor cells increase their proteolytic capability that allows them to break down the basement membrane and to facilitate the first step toward becoming a metastasizing cancer cell. The second hurdle metastasizing tumor cells face is the insult in the lymphatic and blood system by factors that exert a tumor surveillance function. One of such factors is the death ligand TRAIL, which acts through two functional receptors (TRAIL-R1 and TRAIL-R2) and has come to prominence owing to its tumor-specific cell-killing effect. Although, its physiological role has not been completely elucidated, a strong body of evidence exists that it is actively involved in the body's tumor surveillance system that seeks to eradicate transformed cells. To this end, Cretney et al. (2002) have shown that in TRAIL knockout mice, experimental tumors grow more aggressively and tend to spread to other tissues more readily pointing to a substantial role of TRAIL as an effector molecule that is able to eliminate developing tumors. To this end, we could show that MnSOD overexpression protects from TRAIL-induced apoptosis representing a mechanism that might be utilized by tumor cells to escape the tumor-surveillance functions exerted by TRAIL.
As to a possible mechanism of how MnSOD can prevent TRAIL-induced apoptosis, many studies in various cell lines have shown an involvement of increased reactive oxygen species (ROS) production in apoptosis, even in response to cytokines including TNFa and TRAIL (Buttke and Sandstrom, 1995; Lee et al., 2002; Izeradjene et al., 2005) . Our studies indicate that TRAIL induces ROS generation in mitochondria and that this process is involved in the release of proapoptotic factors such as cytochrome c and Smac/ DIABLO. Alternatively, cytosolic free radicals act on mitochondria triggering the release of these factors. In both cases, MnSOD overexpression can block the mitochondrial activation most likely by inhibition of the TRAIL-induced O 2 À accumulation before it can trigger its deadly program inside the mitochondria. Moreover, we found that the increased mitochondrial superoxide dismutase activity in our clones specifically blocked Smac/DIABLO release and thereby apoptosis.
MnSOD expression is positively controlled by NFkB, and it is known that constitutive upregulation of this transcription factor contributes to tumor progression and resistance to cytotoxic drugs as well as several cytokines including TRAIL (Braeuer et al., 2006) . Hence, increased NF-kB activity can give rise to The blots show that cytochrome c release from the mitochondria into the cytosol following TRAIL treatment is substantially reduced in HCTMnS14 cells and Smac/DIABLO release is completely blocked. Cox IV and CuZnSOD are mitochondrial and cytosolic markers, respectively, and also serve as loading controls. (d) Activation of caspase-9 following TRAIL treatment is detected by processing of the pro-caspase form. In HCTCon cells, caspase-9 is readily processed after TRAIL stimulation, whereas in HCTMnS14 this activation is substantially attenuated. (e) Silencing of caspase-9 by RNAi is effective using an adenoviral vector (Ad.shRNAC9), but (f) has no influence on TRAIL-induced apoptosis levels in HCT116 cells. (g) Western blots of HCTCon and HCTMnS14 reveal no difference in the levels of XIAP, ruling out that MnSOD overexpression upregulates XIAP and thereby contributes to or causes apoptosis resistance. (h) Western blots of HCTCon (left) and HCTMnS14 cells (right) that were transduced with an adenoviral vector that expresses a small hairpin RNA motif against XIAP (Ad.shRNA.XIAP). Compared to a control vector that expresses a shRNA motif against EGFP and untransduced cells (untr.) cells, Ad.shRNA.XIAP gives rise to a marked knock down of XIAP in both HCTCon and HCTMnS14 cells. CuZnSOD serves as loading control. (i) The apoptosis levels of Ad.shRNA.XIAP-transduced HCTMnS14 cells (white bars) following treatment with TRAIL are significantly increased over untransduced and Ad.shRNA.EGFP-transduced cells, whereas the apoptosis levels in HCTCon cells (black bars) are not influenced by XIAP silencing. (j) A caspase-3 assay shows that caspase-3 activity is increased in Ad.shRNA.XIAP (white bars)-transduced HCTMnS14 cells as compared to Ad.shRNA.EGFP (black bars) controltransduced cells, demonstrating that knocking down XIAP liberates caspase-3 activity and consequently leads to enhanced TRAIL sensitivity. In HCTCon cells, no difference between Ad.shRNA.XIAP (white bars) and Ad.shRNA.EGFP (black bars) can be detected. (k) The increased caspase-3 activity in HCTMnS14 cells transduced with Ad.shRNA.XIAP and treated with TRAIL is confirmed by the restoration of full cleavage of caspase-3 to its active fragments shown in this western blot.
elevated MnSOD levels that in turn contributes to metastasis formation by various mechanisms including activation of matrix-metalloprotease enzymes and TRAIL resistance. In colon cancer, as well as other tumor types, constitutively elevated levels of NF-kB have also been described (Wang et al., 1999; Smirnov et al., 2001) and recently, Toruner et al. (2006) linked this phenotype to resistance to anoikis by increased expression of osteoprotegerin (OPG), which is a secreted and soluble TRAIL receptor. OPG can function as a decoy receptor or TRAIL and also block the tumor surveillance and antimetastasis activity of TRAIL. Here, we show an alternative or additional mechanism of how metastasizing colorectal cancer cells can escape elimination by TRAIL. Increased levels of MnSOD that are also capable of upregulating proteolytic enzymes that are required for the metastatic process, might also afford the apoptosis resistance necessary to survive the attacks by TRAIL and possibly other cytokines/death ligands. Furthermore, we could demonstrate that we could reverse this MnSOD-mediated resistance by inhibiting the antiapoptotic factor XIAP, which blocks caspase-3 activity and consequently reduces apoptosis. Hence, beyond inhibition of MnSOD, targeting XIAP either by RNAi or pharmacological inhibitors (Fulda et al., 2002; Li et al., 2004) might provide an opportunity to break apoptosis resistance of disseminating tumor cells.
Materials and methods
Cell lines and stable transfection
The HCT116, HT-29 cells and the two HCTMnS clones (HCTMnS9 and HCTMnS14) were cultured in McCoy's medium supplemented with 10% fetal calf serum (FCS) and 1% penicillin-streptomycin (P/S). FCS and P/S were purchased from Biochrom (Berlin, Germany). HCTMnS cells were established by stable transfection of pcDNA3.1-MnSOD that contains the human sequence of MnSOD together with the vector pSV.puro and subsequent selection with 2.5 mg/ml puromycin. Homogeneity in transgene expression was achieved by subcloning MnSOD-overexpressing cell lines in 96-well plates. MnSOD expression was determined by western blot analysis. Clones that were transfected with pSV.puro only were isolated and compared to the HCT116 parental cells. These pSV.puro clones did not differ in growth behavior and TRAIL-induced apoptosis levels from their parental cells. They also showed the same caspase activation profile and Smac/DIABLO release. One clone named HCTCon was used as control cell line throughout our experiments. Moreover, we independently generated HCT116 MnSOD-overexpressing clones using a G418 selection based on the neomycin resistance cassette of pcDNA3.1-MnSOD. Two clones from this selection were further analysed and also showed resistance to TRAIL, whereas control clones were undistinguishable from HCT116 cells (data not shown).
Reagents and antibodies
If not otherwise stated, all reagents were purchased from Sigma (St Louis, MO, USA). Antibodies used in the present study were: rabbit polyclonal anti-MnSOD (StressGene, Victoria, BC, Canada), sheep polyclonal anti-CuZnSOD Horseradish peroxidase-conjugated secondary antibodies were anti-mouse, anti-rabbit and anti-sheep from Santa Cruz (Santa Cruz, CA, USA). For the TRAIL receptor stain, we used the anti-TRAIL Receptor-1 to -4 Flow Cytometry Set from Alexis (San Diego, CA, USA). The secondary antibody, a goat anti-mouse immunoglobulin G (IgG)1 conjugated to R-phycoerythrin, was purchased from Caltag (Carlsbad, CA, USA). The staining was carried out following the instruction provided by the manufacturer of the primary antibodies.
Recombinant TRAIL was purchased from R&D Systems and DIOC6(3) from Invitrogen (Carlsbad, CA, USA).
Western blot
Cells were washed in ice-cold phosphate-buffered saline (PBS), harvested and cell pellets were extracted for 40 min with lysis buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 10% glycerol, 1 mM dithiothreitol (DTT), 1 mM ethylenedinitrilotetraacetic acid, 1% NP-40, plus Roche Complete protease inhibitors, Basle, Switzerland) on ice. Extracts were cleared by centrifugation for 15 min at 12 000 g at 41C. After determination of protein concentrations, samples were denatured in sample buffer (1% sodium dodecyl sulfate (SDS), 0.1% bromophenolblue, 10% glycerol) separated on SDS-polyacrylamide gels and transferred to a polyvinylidene fluoride membrane (Hybond-P; Amersham, Uppsala, Sweden). The membranes were blocked for 1 h in blocking buffer (3% nonfat dry milk solution and 0.1% Tween-20 in Tris-buffered saline (TBS)) and subsequently probed with the indicated primary antibodies in blocking buffer overnight. After three washing steps in wash buffer (0.1% Tween-20 in TBS), the blots were subjected to secondary horse radish peroxidase-conjugated anti-rabbit (Santa Cruz), anti-mouse (Santa Cruz) or antisheep (Santa Cruz) antibodies for 1 h in blocking buffer. After three washing steps in TBS/0.1% Tween-20 and two washes in TBS, proteins were visualized by cheminoluminescence detection (ECL solution, Amersham). Western blots were quantified with the Scion image analysis software package.
Measurement of apoptosis
The determination of apoptotic cells in untreated cultures of HCTCon and HCTMnS were performed according to a protocol by Nicoletti et al. (1991) . Cells were harvested, washed and stained overnight in a buffer containing PI and 0.1% Triton X-100. After incubation at 41C for 16 h, 6000 cells were analysed by flow cytometry (FACS Cantor; Becton Dickinson, Bedford, MA, USA) in the Fl-3 channel on a logarithmic scale and sub-G 1 cells were counted as apoptotic. The Annexin-V/PI staining was carried out as follows: cells were treated with TRAIL and harvested 24 h later. They were trypsinized and spun down at 300 g for 7 min at 41C. Subsequently, cells were washed with Sterofundin (Braun, Melsungen, Germany) supplemented with 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, pH 8.0) and recentrifuged. The cell pellets were resuspended in Annexin V-APC (Bender MedSystems, Vienna, Austria) staining solution (15 ml sterofundin/HEPES, 5 ml Annexin V-APC per sample) and incubated for 15 min at 41C in the dark. Shortly before the measurement, 4 mg/ml of PI were added. Samples were immediately analysed on a FACS Cantor Cytometer (Becton Dickinson). A minimum of 30 000 events per sample were acquired, saved and subsequently analysed with the FloJo software package (Tree Star, Ashland, OR, USA).
Colony-forming assay Cells were treated with 5 ng/ml TRAIL for 1 h and then counted. A total of 100, 1000 and 10 4 cells were seeded into a 10 cm tissue culture plate and cultured for 12 days. The colonies were then fixed in 100% ethanol for 10 min before they were stained with crystal violet and counted.
Laser scanning immunofluorescence microscopy Cells were grown on glass coverslips in medium containing MitoTracker Green. Cells grown on coverslips were first washed in PBS containing 0.1 mM MgCl 2 . Cells were then fixed in ice-cold methanol/acetone 1:1 for 20 min at À201C. After two washing steps with PBS/MgCl 2 , the samples were blocked in PBS/3% bovine serum albumin for 20 min at room temperature followed by incubation steps with primary antiMnSOD antibody for 1 h. Cells were washed three times with PBS/0.2% Tween-20 (5 min each). Then cells were incubated with the Cy3-conjugated secondary anti-mouse antibody (Jackson ImmunoResearch, West Grove, PA, USA) for 1 h in PBS before they were washed again and finally mounted on glass slides. Images were taken on a Zeiss laser scanning microscope LSM510 (Zeiss, Oberkochen, Germany).
MnSOD activity assay
MnSOD activity was measured as previously described (Spitz and Oberley, 1989) . Briefly, equal microgram quantities of total cellular protein were placed in a solution containing 1 mM diethylenetriamine-pentaacetic acid, 5.6 Â 10 À5 M NBT, 10 À4 M xanthine, with 5 mM NaCN (CuZnSOD is inhibited by NaCN). Xanthine oxidase was added to initiate the reaction and the rate of formation of colored product at 560 nm determined. This rate is compared to that measured with no protein to determine inhibition of the reaction by MnSOD. One unit of superoxide dismutase (SOD) activity was defined as the amount of enzyme needed to generate a 50% reduction in the formation of oxidized NBT product.
Adenovirus production and transduction Recombinant E1-deleted adenoviral vectors were generated using the ViraPower adenoviral expression system (Invitrogen) and produced as previously described (Behrend et al., 2005) . Adenoviral vectors encoded small hairpin constructs targeted against MnSOD (GGTTGGCTTGGTTTCAATA), Bid (GA AGACAUCAUCCGGAAUA), caspase-9 (GCTTCGTTTCT GCGAACTAAC), XIAP (GTGGTAGTCCTGTTTCAGC) and the enhanced green fluorescent protein (EGFP) (GTA-CAACTACAACAGCCAC) genes, respectively, under the control of the human U6 promoter (Braeuer et al., 2006) . The Ad.MnSOD and Ad.GFP were generated as described earlier (Zwacka et al., 1998a; Davis et al., 2001) . They express the human MnSOD and GFP cDNAs, respectively, under the control of the CMV early-promoter/-enhancer element. Purified high titer stocks of recombinant adenovirus were generated by two sequential rounds of CsCl 2 banding and desalted by gel filtration in TBS on a Sephadex G-50 column. Viral titers were measured by determining the OD 280 of our viral preparations (OD 280 Â 10 12 ¼ viral particles/ml) and checked by plaque assays on 293 cells. Multiplicity of infection (MOI) is expressed as plaque-forming units per cell. The numbers of viral particles required to generate one plaque was found to be 25 for the viral vectors used. Viral transductions were performed in medium containing 2% FCS and 1% P/S for 16 h at an MOI of 100.
Measurement of the mitochondrial membrane potential
Perturbations in mitochondrial transmembrane potential were monitored by flow cytometry. A total of 10 6 cells were treated with 5 ng/ml TRAIL for 24 h, or left untreated as control. Following TRAIL treatment, cells were harvested and washed with prewarmed PBS. The cells were then labeled with 40 nM DIOC6(3) at 371C for 20 min and subsequently analysed by flow cytometry on a FACS Cantor Cytometer (Becton Dickinson). A minimum of 20 000 events per sample were acquired, saved and subsequently analysed with the FloJo software package (Tree Star).
Caspase activity assay Cells were lysed in assay buffer (100 mM HEPES, 10% sucrose, 2 mM DTT, 0.0001% NP-40 and 0.1% 3-[(3-cholamidopropyl) dimethylammonio] propane-1-sulphonic acid (Chaps), pH 7.25) for 10 min on ice. The protein concentration was measured and adjusted to 1 mg/ml with assay buffer. A total of 100 ml of these crude lysates was transferred to a black 96-well plate and supplemented with 20 mM of the caspase-3 substrate Ac-DEVD-AFC (Biomol, Hamburg, Germany) in assay buffer. After 5 min of incubation/equilibration, the change in fluorescence (excitation, 400 nm; emission, 508 nm) at 301C using a Cytofluor 2000 was measured. Liberated 7-amino-4-trifluoromethyl coumarin (AFC) was measured kinetically every 60 s, for 50 repeats. The rate of AFC formation was used to calculate the caspase-3 activity in the extracts of untreated vs treated cells, and expressed as delta-FU.
Cell fractionation
For the purification of mitochondria, we used the ApoAlert Cell Fractionation Kit from BD Clontech according to the manufacturer's instructions. The western blots were carried out as described with the monoclonal anti-Smac/DIABLO and the antibodies (anti-cytochrome c and anti-CoxIV) that are provided with the kit as well as the anti-CuZnSOD antibody.
